Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of zanidatamab plus standard therapy versus standard therapy alone in HER2-positive advanced biliary tract cancer
MOH_2024-05-20_013420Phase 3Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zanidatamab in biliary cancer, gallbladder cancer, intrahepatic cholangiocarcinoma (ICC) and 1 more (2 arms), sponsored by Jazz Pharmaceuticals plc. Started May 2024; status: active, not recruiting.
02
Drugs
zanidatamab
03
Conditions
biliary cancergallbladder cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on MOH_2024-05-20_013420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-20_013420.